Emerging roles of thioredoxin cycle enzymes in the central nervous system

Cellular and Molecular Life Sciences

Volumn 62, Issue 10, 2005, Pages 1063-1080

  Patenaude, A ^a   Murthy, M R V ^b   Mirault, M E ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Antioxidants; Apoptosis; Brain; Mitochondria; Neurodegeneration; Oxidative stress; Peroxiredoxins; Thioredoxin

Indexed keywords

NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRESENILIN 1; PRION PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT THIOREDOXIN 1; SELENIUM; THIOREDOXIN; THIOREDOXIN PEROXIDASE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ASTROCYTOMA; BRAIN FUNCTION; BRAIN REGION; CELL SECRETION; CENTRAL NERVOUS SYSTEM; GLIA CELL; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN INTERACTION; REVIEW; UPREGULATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; GENE EXPRESSION; HUMANS; NERVE GROWTH FACTORS; OXIDATION-REDUCTION; PEROXIDASES; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH);

ANIMALIA; MUS MUSCULUS;

EID: 20944435890     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-005-4541-5     Document Type: Review

References (215)

1. Ischiropoulos H. and Beckman J. S. (2003) Oxidative stress and nitration in neurodegeneration: cause, effect or association? J. Clin. Invest. 111: 163-169
2. Giasson B. I., Ischiropoulos H., Lee V. M. and Trojanowski J. Q. (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic. Biol. Med. 32: 1264-1275
3. Mattson M. P. (2000) Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell. Biol. 1: 120-129
4. Mattson M. P. and Liu D. (2002) Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med. 2: 215-231
5. Wallace D. C. (1999) Mitochondrial diseases in man and mouse. Science 283: 1482-1488
6. Wallace D. C. (1992) Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 256: 628-632
7. Nicholls D. G. and Budd S. L. (2000) Mitochondria and neuronal survival. Physiol. Rev. 80: 315-360
8. Sagara J. I., Miura K. and Bannai S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61: 1672-1676
9. Damier P., Hirsch E. C., Zhang P., Agid Y. and Javoy-Agid F. (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52: 1-6
10. Harman D. (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol. 11: 298-300
11. Harman D. (2003) The free radical theory of aging. Antioxid Redox Signal. 5: 557-561
12. Sohal R. S. and Weindruch R. (1996) Oxidative stress, caloric restriction and aging. Science 273: 59-63
13. Dawson T. M. and Dawson V. L. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302: 819-822
14. Montine T. J., Neely M. D., Quinn J. F., Seal M. F., Markesbery W. R., Roberts L. J. et al. (2002) Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med. 33: 620-626
15. Botella J. A., Ulschmid J. K., Gruenewald C., Moehle C., Kretzschmar D., Becker K. et al. (2004) The Drosophila carbonyl reductase sniffer prevents oxidative stress-induced neurodegeneration. Curr. Biol. 14: 782-786
16. Sies H. (1993) Strategies of antioxidant defense. Eur. J. Biochem. 215: 213-219
17. Arner E. S. and Holmgren A. (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267: 6102-6109
18. Fernandes A. P. and Holmgren A. (2004) Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid. Redox Signal. 6: 63-74
19. Trépanier G., Furling D., Puymirat J. and Mirault M.-E. (1996) Immunocytochemical localization of seleno-glutathione peroxidase in the adult mouse brain. Neuroscience 75: 231-243
20. Mirault M.-E., Tremblay A., Furling D., Trépanier G., Dugré F., Puymirat J. et al. (1994) Transgenic glutathione peroxidase mouse models for neuroprotection studies. Ann. N. Y. Acad. Sci. 738: 104-115
21. Furling D., Ghribi O., Lahsaini A., Mirault M.-E. and Massicotte G. (2000) Impairment of synaptic transmission by transient hypoxia in hippocampal slices: improved recovery in glutathione peroxidase transgenic mice. Proc. Natl. Acad. Sci. USA 97: 4351-4356
22. Crack P. J., Taylor J. M., Flentjar N. J., de Haan J., Hertzog P., Iannello R. C. et al. (2001) Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-1 (Gpx-1) knockout mouse brain in response to ischemia/reperfusion injury. J. Neurochem. 78: 1389-1399
23. Ishibashi N., Prokopenko O., Weisbrot-Lefkowitz M., Reuhl K. R. and Mirochnitchenko O. (2002) Glutathione peroxidase inhibits cell death and glial activation following experimental stroke. Brain Res. Mol. Brain Res. 109: 34-44
24. Przedborski S., Kostic V., Jackson-Lewis V., Nairn A. B., Simonetti S., Fahn S. et al. (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12: 1658-1667
25. Klivenyi P., Andreassen O. A., Ferrante R. J., Dedeoglu A., Mueller G., Lancelot E. et al. (2000) Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci. 20: 1-7
26. Zhang J., Graham D. G., Montine T. J. and Ho Y. S. (2000) Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J. Neuropathol. Exp. Neurol. 59: 53-61
27. Julien J. P. (2001) Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 104: 581-591
28. Liu R., Li B., Flanagan S. W., Oberley L. W., Gozal D. and Qiu M. (2002) Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD1-mediated motor neuron cell death and increase amyotrophic lateral sclerosis-like transgenic mouse survival. J. Neurochem. 80: 488-500
29. Beretta S., Sala G., Mattavelli L., Ceresa C., Casciati A., Ferri A. et al. (2003) Mitochondrial dysfunction due to mutant copper/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine. Neurobiol. Dis. 13: 213-221
30. Pasinelli P., Belford M. E., Lennon N., Bacskai B. J., Hyman B. T., Trotti D. et al. (2004) Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 43: 19-30
31. Liu J., Lillo C., Jonsson P. A., Vande Velde C., Ward C. M., Miller T. M. et al. (2004) Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron. 43: 5-17
32. Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science 262: 689-695
33. Calabrese V., Scapagnini G., Giuffrida Stella A. M., Bates T. E. and Clark J. B. (2001) Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem. Res. 26: 739-764
34. Beal M. F. (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 1366: 211-223
35. Schafer F. Q. and Buettner G. R. (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30: 1191-1212
36. Mitsui A., Hirakawa T. and Yodoi J. (1992) Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin. Biochem Biophys Res Commun. 186: 1220-1226
37. Holmgren A. (1985) Thioredoxin. Annu. Rev. Biochem. 54: 237-271
38. Nordberg J. and Arner E. S. (2001) Reactive oxygen species, antioxidants and the mammalian thioredoxin system. Free Radic. Biol. Med. 31: 1287-1312
39. Baker A., Payne C. M., Briehl M. M. and Powis G. (1997) Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 57: 5162-5167
40. Berggren M., Gallegos A., Gasdaska J. R., Gasdaska P. Y., Warneke J. and Powis G. (1996) Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16: 3459-3466
41. Gasdaska P. Y., Oblong J. E., Cotgreave I. A. and Powis G. (1994) The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim. Biophys. Acta 1218: 292-296
42. Kawahara N., Tanaka T., Yokomizo A., Nanri H., Ono M., Wada M. et al. (1996) Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res. 56: 5330-5333
43. Powis G., Mustacich D. and Coon A. (2000) The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med. 29: 312-322
44. Soini Y., Kahlos K., Napankangas U., Kaarteenaho-Wiik R., Saily M., Koistinen P. et al. (2001) Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin. Cancer Res. 7: 1750-1757
45. Haapasalo H., Kylaniemi M., Paunul N., Kinnula V. L. and Soini Y. (2003) Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol. 13: 155-164
46. Mustacich D. and Powis G. (2000) Thioredoxin reductase. Biochem. J. 346(Pt 1): 1-8
47. Powis G. and Montfort W. R. (2001) Properties and biological activities of thioredoxins. Annu. Rev. Pharmacol. Toxicol. 41: 261-295
48. Hirota K., Nakamura H., Masutani H. and Yodoi J. (2002) Thioredoxin superfamily and thioredoxin-inducing agents. Ann. N. Y. Acad. Sci. 957: 189-199
49. Butterfield L. H., Merino A., Golub S. H. and Shau H. (1999) From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid. Redox Signal. 1: 385-402
50. Chae H. Z., Kang S. W. and Rhee S. G. (1999) Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. Methods Enzymol. 300: 219-226
51. Fujii J. and Ikeda Y. (2002) Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep. 7: 123-130
52. Rhee S. G., Kang S. W., Chang T. S., Jeong W. and Kim K. (2001) Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52: 35-41
53. Wood Z. A., Schroder E., Robin Harris J. and Poole L. B. (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28: 3-40
54. Laurent T. C., Moore E. C. and Reichard P. (1964) Enzymatic synthesis of deoxyribonucleotides. Iv. isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem. 239: 3436-3444
55. Moore E. C. (1967) A thioredoxin - thioredoxin reductase system from rat tumor. Biochem. Biophys. Res. Commun. 29: 264-268
56. Zhong L., Arner E. S. and Holmgren A. (2000) Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc. Natl. Acad. Sci. USA 97: 5854-5859
57. Chae H. Z., Robison K., Poole L. B., Church G., Storz G. and Rhee S. G. (1994) Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc. Natl. Acad. Sci. USA 91: 7017-7021
58. Das K. C. and Das C. K. (2000) Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions. Biochem. Biophys. Res. Commun. 277: 443-447
59. Matsui M., Oshima M., Oshima H., Takaku K., Maruyama T., Yodoi J. et al. (1996) Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev. Biol. 178: 179-185
60. Wei S. J., Botero A., Hirota K., Bradbury C. M., Markovina S., Laszlo A. et al. (2000) Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res. 60: 6688-6695
61. Ueno M., Masutani H., Arai R. J., Yamauchi A., Hirota K., Sakai T. et al. (1999) Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J. Biol. Chem. 274: 35809-35815
62. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K. and Yodoi J. (1997) AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 94: 3633-3638
63. Hirota K., Murata M., Sachi Y., Nakamura H., Takeuchi J., Mori K. et al. (1999) Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J. Biol. Chem. 274: 27891-27897
64. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y. et al. (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17: 2596-2606
65. Rubartelli A., Bajetto A., Allavena G., Wollman E. and Sitia R. (1992) Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem. 267: 24161-24164
66. Pedrajas J. R., Kosmidou E., Miranda-Vizuete A., Gustafsson J. A., Wright A. P. and Spyrou G. (1999) Identification and functional characterization of a novel mitochondrial thioredoxin system in Saccharomyces cerevisiae. J. Biol. Chem. 274: 6366-6373
67. Spyrou G., Enmark E., Miranda-Vizuete A. and Gustafsson J. (1997) Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem. 272: 2936-2941
68. Damdimopoulos A. E., Miranda-Vizuete A., Pelto-Huikko M., Gustafsson J. A. and Spyrou G. (2002) Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. J. Biol. Chem. 277: 33249-33257
69. Tanaka T., Hosoi F., Yamaguchi-Iwai Y., Nakamura H., Masutani H., Ueda S. et al. (2002) Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J. 21: 1695-1703
70. Nonn L., Williams R. R., Erickson R. P. and Powis G. (2003) The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly and early embryonic lethality in homozygous mice. Mol. Cell. Biol. 23: 916-922
71. Chen Y., Cai J., Murphy T. J. and Jones D. P. (2002) Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. J. Biol. Chem. 277: 33242-33248
72. Matsuo Y., Akiyama N., Nakamura H., Yodoi J., Noda M. and Kizaka-Kondoh S. (2001) Identification of a novel thioredoxin-related transmembrane protein. J. Biol. Chem. 276: 10032-10038
73. Sadek C. M., Jimenez A., Damdimopoulos A. E., Kieselbach T., Nord M., Gustafsson J. A. et al. (2003) Characterization of human thioredoxin-like 2. A novel microtubule-binding thioredoxin expressed predominantly in the cilia of lung airway epithelium and spermatid manchette and axoneme. J. Biol. Chem. 278: 13133-13142
74. Stemme S., Hansson H. A., Holmgren A. and Rozell B. (1985) Axoplasmic transport of thioredoxin and thioredoxin reductase in rat sciatic nerve. Brain Res. 359: 140-146
75. Lippoldt A., Padilla C. A., Gerst H., Andbjer B., Richter E., Holmgren A. et al. (1995) Localization of thioredoxin in the rat brain and functional implications. J. Neurosci. 15: 6747-6756
76. Tomimoto H., Akiguchi I., Wakita H., Kimura J., Hori K. and Yodoi J. (1993) Astroglial expression of ATL-derived factor, a human thioredoxin homologue, in the gerbil brain after transient global ischemia. Brain Res. 625: 1-8
77. Takagi Y., Horikawa F., Nozaki K., Sugino T., Hashimoto N. and Yodoi J. (1998) Expression and distribution of redox regulatory protein, thioredoxin during transient focal brain ischemia in the rat. Neurosci. Lett. 251: 25-28
78. Takagi Y., Tokime T., Nozaki K., Gon Y., Kikuchi H. and Yodoi J. (1998) Redox control of neuronal damage during brain ischemia after middle cerebral artery occlusion in the rat: immunohistochemical and hybridization studies of thioredoxin. J. Cereb. Blood Flow Metab. 18: 206-214
79. Asahina M., Yamada T., Yoshiyama Y. and Yodoi J. (1998) Expression of adult T cell leukemia-derived factor in human brain and peripheral nerve tissues. Dement. Geriatr. Cogn. Disord. 9: 181-185
80. Rybnikova E., Damdimopoulos A. E., Gustafsson J. A., Spyrou G. and Pelto-Huikko M. (2000) Expression of novel antioxidant thioredoxin-2 in the rat brain. Eur. J. Neurosci. 12: 1669-1678
81. Mansur K., Iwahashi Y., Kiryu-Seo S., Su Q., Namikawa K., Yodoi J., et al. (1998) Up-regulation of thioredoxin expression in motor neurons after nerve injury. Brain Res. Mol. Brain Res. 62: 86-91
82. Hattori I., Takagi Y., Nozaki K., Kondo N., Bai J., Nakamura H. et al. (2002) Hypoxia-ischemia induces thioredoxin expression and nitrotyrosine formation in new-born rat brain. Redox Rep. 7: 256-259
83. Yamagata K., Tagami M., Ikeda K., Yamori Y. and Nara Y. (2000) Altered gene expressions during hypoxia and reoxygenation in cortical neurons isolated from stroke-prone spontaneously hypertensive rats. Neurosci. Lett. 284: 131-134
84. Kim Y. C., Yamaguchi Y., Kondo N., Masutani H. and Yodoi J. (2003) Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene 22: 1860-1865
85. Kaghad M., Dessarps F., Jacquemin-Sablon H., Caput D., Fradelizi D. and Wollman E. E. (1994) Genomic cloning of human thioredoxin-encoding gene: mapping of the transcription start point and analysis of the promoter. Gene 140: 273-278
86. Masutani H., Hirota K., Sasada T., Ueda-Taniguchi Y., Taniguchi Y., Sono H. et al. (1996) Transactivation of an inducible anti-oxidative stress protein, human thioredoxin by HTLV-I Tax. Immunol. Lett. 54: 67-71
87. Taniguchi Y., Taniguchi-Ueda Y., Mori K. and Yodoi J. (1996) A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic Acids Res. 24: 2746-2752
88. Nakaso K., Yano H., Fukuhara Y., Takeshima T., Wada-Isoe K. and Nakashima K. (2003) PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. FEBS Lett. 546: 181-184
89. Andoh T., Chock P. B. and Chiueh C. C. (2002) The roles of thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells. J. Biol. Chem. 277: 9655-9660
90. Reddy P. G., Bhuyan D. K. and Bhuyan K. C. (1999) Lens-specific regulation of the thioredoxin-1 gene, but not thioredoxin-2, upon in vivo photochemical oxidative stress in the Emory mouse. Biochem. Biophys. Res. Commun. 265: 345-349
91. Hori K., Katayama M., Sato N., Ishii K., Waga S. and Yodoi J. (1994) Neuroprotection by glial cells through adult T cell leukemia-derived factor/human thioredoxin (ADF/TRX). Brain Res. 652: 304-310
92. Takagi Y., Mitsui A., Nishiyama A., Nozaki K., Sono H., Gon Y. et al. (1999) Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc. Natl. Acad. Sci. USA 96: 4131-4136
93. Mitsui A., Hamuro J., Nakamura H., Kondo N., Hirabayashi Y., Ishizaki-Koizumi S. et al. (2002) Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid. Redox Signal. 4: 693-696
94. Takagi Y., Hattori I., Nozaki K., Mitsui A., Ishikawa M., Hashimoto N. et al. (2000) Excitotoxic hippocampal injury is attenuated in thioredoxin transgenic mice. J. Cereb. Blood Flow Metab. 20: 829-833
95. Hattori I., Takagi Y., Nakamura H., Nozaki K., Bai J., Kondo N. et al. (2004) Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid. Redox Signal. 6: 81-87
96. Lo D. C. (1992) Signal transduction and regulation of neurotrophins. Curr. Opin. Neurobiol. 2: 336-340
97. Huang E. J. and Reichardt L. F. (2001) Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24: 677-736
98. Kruijer W., Schubert D. and Verma I. M. (1985) Induction of the proto-oncogene fos by nerve growth factor. Proc. Natl. Acad. Sci. USA 82: 7330-7334
99. Greenberg M. E., Greene L. A. and Ziff E. B. (1985) Nerve growth factor and epidermal growth factor induce rapid transient changes in proto-oncogene transcription in PC12 cells. J. Biol. Chem. 260: 14101-14110
100. Bai J., Nakamura H., Kwon Y. W., Hattori I., Yamaguchi Y., Kim Y. C. et al. (2003) Critical roles of thioredoxin in nerve growth factor-mediated signal transduction and neurite outgrowth in PC12 cells. J. Neurosci. 23: 503-509
101. Masutani H., Bai J., Kim Y. C. and Yodoi J. (2004) Thioredoxin as a neurotrophic cofactor and an important regulator of neuroprotection. Mol. Neurobiol. 29: 229-242
102. Endoh M., Kunishita T. and Tabira T. (1993) Thioredoxin from activated macrophages as a trophic factor for central cholinergic neurons in vitro. Biochem. Biophys. Res. Commun. 192: 760-765
103. Hirota K., Matsui M., Murata M., Takashima Y., Cheng F. S., Itoh T. et al. (2000) Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-kappaB, AP-1, and CREB activation in HEK293 cells. Biochem. Biophys. Res. Commun. 274: 177-182
104. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K. et al. (1999) Molecular mechanisms of transcription activation by HLF and HIF 1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 18: 1905-1914
105. Sheng M. and Greenberg M. E. (1990) The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron. 4: 477-485
106. Sheng M., Dougan S. T., McFadden G. and Greenberg M. E. (1988) Calcium and growth factor pathways of c-fos transcriptional activation require distinct upstream regulatory sequences. Mol. Cell Biol. 8: 2787-2796
107. Meuillet E. J., Mahadevan D., Berggren M., Coon A. and Powis G. (2004) Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch. Biochem. Biophys. 429: 123-133
108. Newton H. B. (2004) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anticancer Ther. 4: 105-128
109. Lovell M. A., Xie C., Gabbita S. P. and Markesbery W. R. (2000) Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic. Biol. Med. 28: 418-427
110. Requena J. R. and Levine R. L. (2001) Thioredoxin converts the Syrian hamster (29-231) recombinant prion protein to an insoluble form. Free Radic. Biol. Med. 30: 141-147
111. Zhang H., Stockel J., Mehlhorn I., Groth D., Baldwin M. A., Prusiner S. B. et al. (1997) Physical studies of conformational plasticity in a recombinant prion protein. Biochemistry 36: 3543-3553
112. Zhou Y., Zhang W., Easton R., Ray J. W., Lampe P., Jiang Z. et al. (2002) Presenilin-1 protects against neuronal apoptosis caused by its interacting protein PAG. Neurobiol. Dis. 9: 126-138
113. DebBurman S. K., Raymond G. J., Caughey B. and Lindquist S. (1997) Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc. Natl. Acad. Sci. USA 94: 13938-13943
114. Hoffmann J. H., Linke K., Graf P. C., Lilie H. and Jakob U. (2004) Identification of a redox-regulated chaperone network. Embo J. 23: 160-168
115. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047
116. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A. and Wolozin B. (2003) Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278: 11753-11759
117. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S. et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608
118. Bonifati V., Rizzu P., van Baren M. J., Schaap O., Breedveld G. J., Krieger E. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259
119. Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M. and Bonini N. M. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295: 865-868
120. Fernando M. R., Nanri H., Yoshitake S., Nagata-Kuno K. and Minakami S. (1992) Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells. Eur. J. Biochem. 209: 917-922
121. Bhat G. B., Iwase K., Hummel B. C. and Walfish P. G. (1989) Kinetic characteristics of a thioredoxin-activated rat hepatic and renal low-Km iodothyronine 5′-deiodinase. Biochem. J. 258: 785-792
122. Flamigni F., Marmiroli S., Caldarera C. M. and Guarnieri C. (1989) Involvement of thiol transferase- and thioredoxin-dependent systems in the protection of 'essential' thiol groups of ornithine decarboxylase. Biochem. J. 259: 111-115
123. Hawkins H. C., Blackburn E. C. and Freedman R. B. (1991) Comparison of the activities of protein disulphide-isomerase and thioredoxin in catalysing disulphide isomerization in a protein substrate. Biochem. J. 275(Pt 2): 349-353
124. Lee S. R., Bar-Noy S., Kwon J., Levine R. L., Stadtman T. C. and Rhee S. G. (2000) Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc. Natl. Acad. Sci. USA 97: 2521-2526
125. Sandalova T., Zhong L., Lindqvist Y., Holmgren A. and Schneider G. (2001) Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc. Natl. Acad. Sci. USA 98: 9533-9538
126. Zhong L. and Holmgren A. (2000) Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J. Biol. Chem. 275: 18121-18128
127. May J. M., Cobb C. E., Mendiratta S., Hill K. E. and Burk R. F. (1998) Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase. J. Biol. Chem. 273: 23039-23045
128. May J. M., Mendiratta S., Hill K. E. and Burk R. F. (1997) Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J. Biol. Chem. 272: 22607-22610
129. Arner E. S., Nordberg J. and Holmgren A. (1996) Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem. Biophys. Res. Commun. 225: 268-274
130. Xia L., Nordman T., Olsson J. M., Damdimopoulos A., Bjorkhem-Bergman L., Nalvarte I. et al. (2003) The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J. Biol. Chem. 278: 2141-2146
131. Bjornstedt M., Hamberg M., Kumar S., Xue J. and Holmgren A. (1995) Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J. Biol. Chem. 270: 11761-11764
132. Arteel G. E., Briviba K. and Sies H. (1999) Function of thioredoxin reductase as a peroxynitrite reductase using selenocystine or ebselen. Chem. Res. Toxicol. 12: 264-269
133. Gasdaska P. Y., Gasdaska J. R., Cochran S. and Powis G. (1995) Cloning and sequencing of a human thioredoxin reductase. FEBS Lett. 373: 5-9
134. Kawai H., Ota T., Suzuki F. and Tatsuka M. (2000) Molecular cloning of mouse thioredoxin reductases. Gene. 242: 321-330.
135. Oberley T. D., Verwiebe E., Zhong W., Kang S. W. and Rhee S. G. (2001) Localization of the thioredoxin system in normal rat kidney. Free Radic. Biol. Med. 30: 412-424
136. Miranda-Vizuete A., Damdimopoulos A. E., Pedrajas J. R., Gustafsson J. A. and Spyrou G. (1999) Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. Eur. J. Biochem. 261: 405-412
137. Miranda-Vizuete A., Damdimopoulos A. E. and Spyrou G. (1999) cDNA cloning, expression and chromosomal localization of the mouse mitochondrial thioredoxin reductase gene(1). Biochim. Biophys. Acta. 1447: 113-118
138. Lee S. R., Kim J. R., Kwon K. S., Yoon H. W., Levine R. L., Ginsburg A. et al. (1999) Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J. Biol. Chem. 274: 4722-4734
139. Watabe S., Hiroi T., Yamamoto Y., Fujioka Y., Hasegawa H., Yago N. et al. (1997) SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria. Eur. J. Biochem. 249: 52-60
140. Watabe S., Makino Y., Ogawa K., Hiroi T., Yamamoto Y. and Takahashi S. Y. (1999) Mitochondrial thioredoxin reductase in bovine adrenal cortex its purification, properties, nucleotide/amino acid sequences, and identification of selenocysteine. Eur. J. Biochem. 264: 74-84
141. Sun Q. A., Kirnarsky L., Sherman S. and Gladyshev V. N. (2001) Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc. Natl. Acad. Sci. USA 98: 3673-3678
142. Sun Q. A., Zappacosta F., Factor V. M., Wirth P. J., Hatfield D. L. and Gladyshev V. N. (2001) Heterogeneity within animal thioredoxin reductases. Evidence for alternative first exon splicing. J. Biol. Chem. 276: 3106-3114
143. Jurado J., Prieto-Alamo M. J., Madrid-Risquez J. and Pueyo C. (2003) Absolute gene expression patterns of thioredoxin and glutaredoxin redox systems in mouse. J. Biol. Chem. 278: 45546-45554
144. Missirlis F., Ulschmid J. K., Hirosawa-Takamori M., Gronke S., Schafer U., Becker K. et al. (2002) Mitochondrial and cytoplasmic thioredoxin reductase variants encoded by a single Drosophila gene are both essential for viability. J. Biol. Chem. 277: 11521-11526
145. Casso D. and Beach D. (1996) A mutation in a thioredoxin reductase homolog suppresses p53-induced growth inhibition in the fission yeast Schizosaccharomyces pombe. Mol. Gen. Genet. 252: 518-529
146. Karimpour S., Lou J., Lin L. L., Rene L. M., Lagunas L., Ma X. et al. (2002) Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene 21: 6317-6327
147. Sakurai A., Yuasa K., Shoji Y., Himeno S., Tsujimoto M., Kunimoto M. et al. (2004) Overexpression of thioredoxin reductase 1 regulates NF-kappa B activation. J. Cell Physiol. 198: 22-30
148. Nalvarte I., Damdimopoulos A. E. and Spyrou G. (2004) Human mitochondrial thioredoxin reductase reduces cytochrome c and confers resistance to complex III inhibition. Free Radic Biol Med. 36: 1270-1278
149. Nalvarte I., Damdimopoulos A. E., Nystrom C., Nordman T., Miranda-Vizuete A., Olsson J. M. et al. (2004) Overexpression of enzymatically active human cytosolic and mitochondrial thioredoxin reductase in HEK-293 cells: effect on cell growth and differentiation. J. Biol. Chem. 279: 54510-54517
150. Patenaude A. (2004) Thiorédoxine réductase mitochondriale: étude de son rôle dans l'apoptose, le rédox et la croissance cellulaires, Ph.D. thesis, Laval University, Québec City
151. Patenaude A., Ven Murthy M. R. and Mirault M. E. (2004) Mitochondrial thioredoxin system: effects of TrxR2 overexpression on redox balance, cell growth and apoptosis. J. Biol. Chem. 279: 27302-27314
152. Rozell B., Hansson H. A., Luthman M. and Holmgren A. (1985) Immunohistochemical localization of thioredoxin and thioredoxin reductase in adult rats. Eur. J. Cell Biol. 38: 79-86
153. Eftekharpour E., Holmgren A. and Juurlink B. H. (2000) Thioredoxin reductase and glutathione synthesis is upregulated by t-butylhydroquinone in cortical astrocytes but not in cortical neurons. Glia 31: 241-248
154. Rayman M. P. (2000) The importance of selenium to human health. Lancet 356: 233-241
155. Schweizer U., Brauer A. U., Kohrle J., Nitsch R. and Savaskan N. E. (2004) Selenium and brain function: a poorly recognized liaison. Brain Res. Brain Res. Rev. 45: 164-178
156. Kyriakopoulos A. and Behne D. (2002) Selenium-containing proteins in mammals and other forms of life. Rev. Physiol. Biochem. Pharmacol. 145: 1-46
157. Kryukov G. V., Castellano S., Novoselov S. V., Lobanov A. V., Zehtab O., Guigo R. et al. (2003) Characterization of mammalian selenoproteomes. Science 300: 1439-1443
158. Stadtman T. C. (1996) Selenocysteine. Annu Rev Biochem. 65: 83-100
159. Chen J. and Berry M. J. (2003) Selenium and selenoproteins in the brain and brain diseases. J. Neurochem. 86: 1-12
160. Burk R. F., Hill K. E. and Motley A. K. (2003) Selenoprotein metabolism and function: evidence for more than one function for selenoprotein P. J. Nutr. 133: 1517S-1520S
161. Hill K. E., McCollum G. W., Boeglin M. E. and Burk R. F. (1997) Thioredoxin reductase activity is decreased by selenium deficiency. Biochem. Biophys. Res. Commun. 234: 293-295
162. Yant L. J., Ran Q., Rao L., Van Remmen H., Shibatani T., Belter J. G. et al. (2003) The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic. Biol. Med. 34: 496-502
163. Weber G. F., Maertens P., Meng X. Z. and Pippenger C. E. (1991) Glutathione peroxidase deficiency and childhood seizures. Lancet 337: 1443-1444
164. Ramaekers V. T., Calomme M., Vanden Berghe D. and Makropoulos W. (1994) Selenium deficiency triggering intractable seizures. Neuropediatrics. 25: 217-223
165. Kim H. C., Jhoo W. K., Choi D. Y., Im D. H., Shin E. J., Suh J. H. et al. (1999) Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain Res. 851: 76-86
166. Zafar K. S., Siddiqui A., Sayeed I., Ahmad M., Salim S. and Islam F. (2003) Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. J. Neurochem. 84: 438-446
167. Hill K. E., Zhou J., McMahan W. J., Motley A. K., Atkins J. F., Gesteland R. F. et al. (2003) Deletion of selenoprotein P alters distribution of selenium
168. Chang T. S., Cho C. S., Park S., Yu S., Kang S. W. and Rhee S. G. (2004) Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem. 279: 41975-41984. Epub 42004 Jul 41927
169. Lovell M. A., Ehmann W. D., Butler S. M. and Markesbery W. R. (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45: 1594-1601
170. Kim K., Kim I. H., Lee K. Y., Rhee S. G. and Stadtman E. R. (1988) The isolation and purification of a specific 'protector' protein which inhibits enzyme inactivation by a thiol/ Fe(III)/O2 mixed-function oxidation system. J. Biol. Chem. 263: 4704-4711
171. Wang X., Phelan S. A., Forsman-Semb K., Taylor E. F., Petros C., Brown A. et al. (2003) Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J. Biol. Chem. 278: 25179-25190
172. Lee S. P., Hwang Y. S., Kim Y. J., Kwon K. S., Kim H. J., Kim K. et al. (2001) Cyclophilin a binds to peroxiredoxins and activates its peroxidase activity. J. Biol. Chem. 276: 29826-29832
173. Kang S. W., Chae H. Z., Seo M. S., Kim K., Baines I. C. and Rhee S. G. (1998) Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J. Biol. Chem. 273: 6297-6302
174. Manevich Y., Sweitzer T., Pak J. H., Feinstein S. I., Muzykantov V. and Fisher A. B. (2002) 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. Proc. Natl. Acad. Sci. USA 99: 11599-11604
175. Kinnula V. L., Lehtonen S., Sormunen R., Kaarteenaho-Wiik R., Kang S. W., Rhee S. G. et al. (2002) Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J. Pathol. 196: 316-323
176. Mizusawa H., Ishii T. and Bannai S. (2000) Peroxiredoxin I (macrophage 23 kDa stress protein) is highly and widely expressed in the rat nervous system. Neurosci. Lett. 283: 57-60
177. Okado-Matsumoto A., Matsumoto A., Fujii J. and Taniguchi N. (2000) Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J. Biochem. (Tokyo) 127: 493-501
178. Seo M. S., Kang S. W., Kim K., Baines I. C., Lee T. H. and Rhee S. G. (2000) Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J. Biol. Chem. 275: 20346-20354
179. Neumann C. A., Krause D. S., Carman C. V., Das S., Dubey D. P., Abraham J. L. et al. (2003) Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565
180. Lee T. H., Kim S. U., Yu S. L., Kim S. H., Park do S., Moon H. B. et al. (2003) Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood 101: 5033-5038
181. Iwahara S., Satoh H., Song D. X., Webb J., Burlingame A. L., Nagae Y. et al. (1995) Purification, characterization and cloning of a heme-binding protein (23 kDa) in rat liver cytosol. Biochemistry 34: 13398-13406
182. Prosperi M. T., Ferbus D., Karczinski I. and Goubin G. (1993) A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J. Biol. Chem. 268: 11050-11056
183. Prosperi M. T., Ferbus D., Rouillard D. and Goubin G. (1998) The pag gene product, a physiological inhibitor of c-abl tyrosine kinase, is overexpressed in cells entering S phase and by contact with agents inducing oxidative stress. FEBS Lett. 423: 39-44
184. Chang T. S., Jeong W., Choi S. Y., Yu S., Kang S. W. and Rhee S. G. (2002) Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation. J. Biol. Chem. 277: 25370-25376
185. Wen S. T. and Van Etten R. A. (1997) The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11: 2456-2467
186. Mu Z. M., Yin X. Y. and Prochownik E. V. (2002) Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J. Biol. Chem. 277: 43175-43184
187. Nonn L., Berggren M. and Powis G. (2003) Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol. Cancer Res. 1: 682-689
188. Choi J. H., Kim T. N., Kim S., Baek S. H., Kim J. H., Lee S. R. et al. (2002) Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 22: 3331-3335
189. Noh D. Y., Ahn S. J., Lee R. A., Kim S. W., Park I. A. and Chae H. Z. (2001) Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 21: 2085-2090
190. Sarafian T. A., Verity M. A., Vinters H. V., Shih C. C., Shi L., Ji X. D. et al. (1999) Differential expression of peroxiredoxin subtypes in human brain cell types. J. Neurosci. Res. 56: 206-212
191. Ichimiya S., Davis J. G., O'Rourke D. M., Katsumata M. and Greene M. I. (1997) Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. DNA Cell Biol. 16: 311-321
192. Matsumoto A., Okado A., Fujii T., Fujii J., Egashira M., Niikawa N. et al. (1999) Cloning of the peroxiredoxin gene family in rats and characterization of the fourth member. FEBS Lett. 443: 246-250
193. Jin D. Y., Chae H. Z., Rhee S. G. and Jeang K. T. (1997) Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J. Biol. Chem. 272: 30952-30961
194. Nakaso K., Kitayama M., Ishii T., Bannai S., Yanagawa T., Kimura K. et al. (1999) Effects of kainate-mediated excitotoxicity on the expression of rat counterparts of A170 and MSP23 stress proteins in the brain. Brain Res. Mol. Brain Res. 69: 155-163
195. Nakaso K., Kitayama M., Mizuta E., Fukuda H., Ishii T., Nakashima K. et al. (2000) Co-induction of heme oxygenase-1 and peroxiredoxin I in astrocytes and microglia around hemorrhagic region in the rat brain. Neurosci. Lett. 293: 49-52
196. Ishii T., Itoh K., Takahashi S., Sato H., Yanagawa T., Katoh Y. et al. (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 275: 16023-16029
197. Hattori F., Murayama N., Noshita T. and Oikawa S. (2003) Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J. Neurochem. 86: 860-868
198. Kim S. H., Fountoulakis M., Cairns N. and Lubec G. (2001) Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J. Neural. Transm. Suppl: 223-235
199. Krapfenbauer K., Engidawork E., Cairns N., Fountoulakis M. and Lubec G. (2003) Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 967: 152-160
200. Chen W., Ji J., Xu X., He S. and Ru B. (2003) Proteomic comparison between human young and old brains by two-dimensional gel electrophoresis and identification of proteins. Int. J. Dev. Neurosci. 21: 209-216
201. Kato S., Saeki Y., Aoki M., Nagai M., Ishigaki A., Itoyama Y. et al. (2004) Histological evidence of redox system breakdown caused by superoxide dismutase 1 (SOD1) aggregation is common to SOD1-mutated motor neurons in humans and animal models. Acta Neuropathol. (Berl) 107: 149-158
202. Krapfenbauer K., Yoo B. C., Fountoulakis M., Mitrova E. and Lubec G. (2002) Expression patterns of antioxidant proteins in brains of patients with sporadic Creutzfeldt-Jacob disease. Electrophoresis 23: 2541-2547
203. Kopacek J., Sakaguchi S., Shigematsu K., Nishida N., Atarashi R., Nakaoke R. et al. (2000) Upregulation of the genes encoding lysosomal hydrolases, a perforin-like protein, and peroxidases in the brains of mice affected with an experimental prion disease. J. Virol. 74: 411-417
204. Plaisant F., Clippe A., Vander Stricht D., Knoops B. and Gressens P. (2003) Recombinant peroxiredoxin 5 protects against excitotoxic brain lesions in newborn mice. Free Radic. Biol. Med. 34: 862-872
205. Rego A. C., Monteiro N. M., Silva A. P., Gil J., Malva J. O. and Oliveira C. R. (2003) Mitochondrial apoptotic cell death and moderate superoxide generation upon selective activation of non-desensitizing AMPA receptors in hippocampal cultures. J. Neurochem. 86: 792-804
206. Dechant G. and Neumann H. (2002) Neurotrophins. Adv. Exp. Med. Biol. 513: 303-334
207. Russo-Neustadt A. (2003) Brain-derived neurotrophic factor, behavior and new directions for the treatment of mental disorders. Semin. Clin. Neuropsychiatry 8: 109-118
208. Nakamura H., Herzenberg L. A., Bai J., Araya S., Kondo N., Nishinaka Y. et al. (2001) Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc. Natl. Acad. Sci. USA 98: 15143-15148
209. Kuroiwa T., Ting P., Martinez H. and Klatzo I. (1985) The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol. (Berl) 68: 122-129
210. Ballabh P., Braun A. and Nedergaard M. (2004) The bloodbrain barrier: an overview: structure, regulation and clinical implications. Neurobiol. Dis. 16: 1-13
211. Sugino T., Nozaki K., Takagi Y., Hattori I., Hashimoto N. and Yodoi J. (1999) Expression and distribution of redox regulatory protein, thioredoxin after metabolic impairment by 3-nitropropionic acid in rat brain. Neurosci. Lett. 275: 145-148
212. Kikuchi S., Shinpo K., Takeuchi M., Tsuji S., Yabe I., Niino M. et al. (2002) Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons. J. Neurosci. Res. 69: 373-381
213. Lee J. M., Shih A. Y. Murphy T. H. and Johnson J. A. (2003) NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J. Biol. Chem. 278: 37948-37956
214. Chiueh C., Lee S., Andoh T. and Murphy D. (2003) Induction of antioxidative and antiapoptotic thioredoxin supports neuroprotective hypothesis of estrogen. Endocrine. 21: 27-31
215. Bai J., Nakamura H., Hattori I., Tanito M. and Yodoi J. (2002) Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells. Neurosci. Lett. 321: 81-84